NeuBase Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Other Prepaid Expenses and Other Current Assets

9 Months Ended

Jun. 30, 2022

3. Other Prepaid Expenses and Other Current Assets

The Company’s prepaid expenses and other current assets consisted of the following:


	As of June 30,		As of September 30,
	2022		2021
Prepaid research and development expense	$	670,420	$	583,267
Prepaid rent		—		172,518
Other prepaid expenses and other current assets		643,637		780,401
Total	$	1,314,057	$	1,536,186